Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
Retrieved on:
Monday, October 18, 2021
Health, Diabetes, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, CF, Instagram, Immunosuppression, Degenerative disease, Death, Program, Duchenne muscular dystrophy, Eye disease, Private Securities Litigation Reform Act, Clinical trial, Awareness, LinkedIn, IND, Nutrient, SAE, Pain, Security (finance), LGBTQ, Nerve Damage, Diet, Human Rights Campaign, Diabetic ketoacidosis, Cystic fibrosis, YouTube, Rash, Severe cognitive impairment, Disease, Patient, Pancreas, Exercise, Biology, Hypoglycemia, Insulin, Seizure, U.S. Securities and Exchange Commission, Sickle cell disease, Annual report, Coma, Beta thalassemia, Twitter, Safety, Stroke, Injury, Research, Consciousness, Pharmaceutical industry, Medical device, VX-880, the Phase 1/2 Clinical Trial, Type 1 Diabetes, Vertex, VX-880, THE PHASE 1/2 CLINICAL TRIAL, TYPE 1 DIABETES, VERTEX
Through Day 90, the patient had one SAE; this was a rash that was mild in severity, not related to VX-880, and resolved.
Key Points:
- Through Day 90, the patient had one SAE; this was a rash that was mild in severity, not related to VX-880, and resolved.
- Based upon these data, Vertex plans to continue to progress the Phase 1/2 program for VX-880.
- There are multiple active sites in the U.S., and the Clinical Trial Application has been approved in Canada.
- VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology.